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S272 Poster Session IIMethods and Patients: Patients were adaptively randomized, based
on day SCT +30 and chimerism status: Arm I Clo:Flu 10:30 mg/m2,
Arm II 20:20 mg/m2, Arm III 30:10 mg/m2, and Arm IV Clo at
40 mg/m2. The NA were/was infused over 60 min each once daily
for 4 d; then Bu was infused over 3 hrs to an average daily AUC of
6,000 mM-min. GVHD-prophylaxis was tacrolimus and mini-
MTX. Recipients of unrelated or one antig-mism related donor cells
received rabbit-ATG.
Results: 41 pts were enrolled, M:F 24:17, median age 45 yrs (range:
6-59). 32 pts had AML (ind. failure: 12, chemotherapy refr. relapse:
8, untreated relapse: 2, CR2 + CR2 p: 6, high-risk CR1: 1 [cytog. -7
and t(3;12)]). 17 of the 32 AML pts had intermediate, 15 had poor
prognosis cytogenetics. 9 pts had CML (BC: 2, second AP: 3, and
late CP: 4). Donors were 51% related; stem cell source was 61%
bone marrow or 39% peripheral blood.
All 41 pts engrafted. Peripheral blood (T-cell) chimerism at day
+30 revealed Arms I + II to have a median of 85% donor-derived
DNA, and Arms III + IV 100% donor-DNA; at day +100 all cohorts
had 100% donor-DNA.There were no secondary graft failures. Due
to the adaptive randomization, most pts were gradually allocated to
Arm III. 19 of the 23 pts with active AML and 7 of the 9 CML pts
enteredCR after SCT.We had 2 treatment-related deaths in the first
100 d (1 pneumonia and 1 GVHD). Grade 2-3 mucositis occurred in
about half the pts, but there were no serious toxicities. The median
follow-up is 16 months; one-year overall and event-free survival
are 52 and 40%, respectively.
Conclusions: 1) [Clo6 Flu] + IV Bu-based conditioning therapy is
safe and efficacious in high-risk pts withML/MDS. 2) The immuno-
suppressive capability of Clo allows its use in pretransplant condi-
tioning. 3) The in vitro studies which showed a superior
cytotoxicity of [Clo + Flu + Bu] than either [Clo + Bu] or [Flu + Bu]
were supported clinically by the better clinical outcomes in Arm
III. Additional pts and longer follow-up are needed to fully evaluate
the efficacy of [Clo + Flu + Bu] in pre-transplant conditioning.307
ASSESSMENT OF THE UTILITY OF SUBSET DONOR CHIMERISM FOR PRE-
DICTING EVENT-FREE SURVIVAL AFTER NON-MYELOABLATIVE ALLOGE-
NEIC HEMATOPOIETIC CELL TRANSPLANTATION USING TLI AND ATG
Logan, A.C.1, Turnbull, B.B.2, Lavori, P.W.2, Miklos, D.B.1,
Negrin, R.S.1, Lowsky, R.1, Kohrt, H.E.1 1Stanford University School of
Medicine, Stanford, CA; 2Stanford University School of Medicine, Stan-
ford, CA
Allogeneic hematopoietic cell transplantation (HCT) following
conditioning with total lymphoid irradiation (TLI) and antithymo-
cyte globulin (ATG) is an effective treatment modality for leukemia
and lymphoma.We recently reported 3-year event-free survival rates
for AML and NHL of 40% and 42%, respectively (Kohrt et al.,
Blood, 114:1099-1109). Disease relapse remains the primary cause
of treatment failure, thus the ability to predict when patients are at
risk for relapse would allow for timely immunologic interventions,
such as alterations of immunosuppressive therapy or donor lympho-
cyte infusions.We analyzed CD3/15/19/56 peripheral blood chime-
rism in 122 patients who underwent allo-HCT after TLI-ATG
conditioning between December 2001 and July 2009. Univariate
analysis comparing complete chimerism (.95% donor CD3) to
mixed chimerism (5-95% donor CD3) did not reliably predict events
(relapse or death). Several methods of evaluating the predictive value
of subset chimerism were then assessed, including Cox regression
analysis of chimerism trajectory, receiver operator characteristic
(ROC) analysis of chimerism trajectory, and ROC analysis of indi-
vidual chimerism measurements at days 90, 120, 150, and 180 after
HCT. Although subset chimerism generally performed poorly as
a predictor of outcome with all analytic strategies, ROC analysis of
chimerism trajectory and individual measurements demonstrated
limited utility for predicting event-free survival. We calculated the
area under the ROC curve (AUC), which represents the probability
that a randomly chosen patient with an observed event has lower chi-
merism than a randomly chosen patient without an observed event.
An AUC greater than 80% represents a high likelihood of event pre-
diction. For patients with lymphoid malignancies, all subsets ex-
hibited poor predictive value using all methods, and with ROC
analysis the AUC was uniformly less than 70% for all subset-time-point combinations. In patients with myeloid malignancies, only
CD15 chimerism was predictive of event-free survival, with AUC
values of 84% at day 90, 79% at day 120, 82% at day 150 and 88%
at day 180. We conclude that subset donor chimerism has little util-
ity for predicting event-free survival in lymphoid malignancies, and
that only CD15 chimerism predicts outcome in myeloid malignan-
cies. Additional patient characteristics will need to be incorporated
into the decision to apply immunological therapies to alter outcome
after non-myeloablative HCT.308
LOW CD4 T-LYMPHOCYTE REACTIVITY BY THE CYLEX IMMUKNOW AS-
SAY PREDICTS VIRAL INFECTIONS FOLLOWING ALLOGENEIC HEMATO-
POIETIC STEM CELL TRANSPLANTATION
Farag, S.S.1, Wood, L.1, Schwartz, J.1, Nelson, R.P.1, Srivastava, S.1,
Secrest, A.1, Cox, E.1, Robertson,M.1, Abonour, R.1, Lobashevsky, A.2 1 In-
diana University School of Medicine and Simon Cancer Center, Indianap-
olis, IN; 2 Indiana University School of Medicine, Indianapolis, IN
Viral infections are a significant cause ofmorbidity after allogeneic
stem cell transplantation. Modifying intensity of immunosuppres-
sion according to immune function may reduce infections. Cur-
rently, no routine functional assays to monitor immune function of
the new graft exist. The Cylex ImmuKnow assay is a FDA approved
test that quantifies cellular immune function by measuring intracel-
lular ATP activity released by PHA-stimulated CD4 T cells in
blood, and has correlated with solid organ graft outcomes.
We correlated ATP activity with viral infections in the first 100
days post-transplant. 341 blood samples were collected q1-3 weeks
from 32 patients of median age 42 (21-59) years undergoing related
(14) or unrelated (18) donor transplants. All received myeloablative
doses of chemotherapy6TBI, with ATG in 14 patients. GvHDpro-
phylaxis included FK506 with sirolimus (28) or methotrexate (4).
CMV and EBV load was monitored in plasma by PCR q1-2 weeks
and preemptive therapy started on reactivation with other viral test-
ing as clinically indicated. 14 patients developed infections while on
GvHD prophylaxis, including CMV (10), EBV (3), BK hemorrhagic
cystitis (8), adenovirus gastritis (1), and HSV pneumonitis (1).
Baseline median ATP activity for all patients was 280 (5-809) ng/
ml, compared to 491 (238-842) ng/ml for healthy volunteers
(P\0.0001). ATP activity only modestly correlated with lympho-
cyte (R25 0.21) and WBC (R25 0.45) counts. Median ATP activi-
ties were lower for patients who developed infections between days
+31 and +60 (31 vs 106 ng/ml, P5 0.0007), and days +61 and +100
(34 vs 139 ng/ml, P5 0.0006). On logistic regression, low ATP ac-
tivity was predictive of infections (P\0.0001), but lymphocyte and
WBC counts were not. Using 90 ng/ml as cutoff, 11 of 20 patients
with ATP activity\100 ng/ml developed infections compared to 1
of 12 with activity $100 ng/ml between days +31 and +60
(P5 0.01). Between days +60 and +100, 9 of 12 patients with levels
\90 ng/ml developed infections, compared to 1 of 14 patients with
levels $90 ng/ml (P5 0.001). Median ATP activity was 251 (97-
494) ng/ml at the onset of grade 2-4 acute GvHD that occurred in
4 patients. Our results indicate that low ATP activity in CD4 T cells
is strongly predictive of viral infections in the first 100 days after
transplant, and suggest that modifying the intensity of immunosup-
pression to maintain ATP activity around 90 ng/ml should be inves-
tigated as a strategy to reduce infections.309
AZITHROMYCIN FOR BRONCHIOLITIS OBLITERANS FOLLOWING ALLO-
GENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION
Maciuleviciute, E.1, Burzynski, J.A.1, Wolf, R.C.1, Ansell, S.M.2,
Buadi, F.K.2, Dingli, D.2, Dispenzieri, A.2, Gastineau, D.A.2,
Gertz, M.A.2, Inwards, D.J.2, Johnston, P.B.2, Kumar, S.2,
Lacy, M.Q.2, Litzow, M.R.2, Micallef, I.N.M.2, Porrata, L.E.2,
Hogan,W.J.2 1Mayo Clinic, Rochester,MN; 2Mayo Clinic, Rochester,MN
Background: Bronchiolitis obliterans (BO) following HSCT is as-
sociated with significant morbidity and mortality with few effective
Poster Session II S273therapies. Current therapy includes corticosteroids and immunosup-
pression. Azithromycin has been used to manage BO following lung
transplantation; however it has been reported in fewHSCT patients.
We report our experience in 46 patients receiving azithromycin for
BO.
Methods: IRB approval and patient consent were obtained prior to
review of electronic medical records and theMayo Clinic HSCT da-
tabase. All adult patients who received a HSCT from 1/1/00 to 8/1/
09 and received azithromycin were included. Patients were excluded
if they refused consent for use of medical records for research, re-
ceived azithromycin for prophylaxis or treatment of infection, or
did notmeet criteria for BO according to the 2001 diagnostic criteria
for BO in lung transplantation. BO stage was based on PFTs follow-
ing these criteria. Baseline demographic characteristics and clinical
endpoints were collected including: change in PFTs, therapy re-
ceived, and survival following BO diagnosis.
Results: From 1/1/00 to 8/1/09, 388 patients underwent alloge-
neic HSCT at Mayo Clinic Rochester; 46 received azithromycin
for BO. 342 patients were excluded: consent refused (n5 1), no
azithromycin (n5 306), azithromycin for treatment of infection
(n5 27), azithromycin for prophylaxis of infection (n5 6), BO
stage 0 (n5 2). Primary diagnosis included AML/MDS (n5 21),
ALL (n5 9), MM (n5 5), CLL (n5 4), CML (n5 3), lymphoma
(n5 3), CMML (n5 1). Median age at diagnosis of BO was 48
years (range 19-68). 25/46 (54%) received a MUD allogeneic
HSCT. 17/46 (37%) received reduced intensity conditioning.
24/46 (52%) received. 1200 cGy TBI. Median time from trans-
plant to BO diagnosis was 363 days (range 98-1822 days). Azithro-
mycin dosing regimens ranged from 250 mg thrice weekly to
500 mg daily. 30 patients received systemic corticosteroids, 31 re-
ceived inhaled corticosteroids, 14 received ECP, and 5 receivedTable 1. Pulmonary Function Tests in Patients with Bronchiolitis Obliterans
Pre-transplant At diagnosis of BO 1 month 3 months 6 months 9 months 12 months
FEV1 891/-15 (n5 46) 551/-16 (n5 46) 631/-22 (n5 39) 641/-23 (n5 28) 581/-26 (n5 28) 631/-27 (n5 17) 521/-19 (n5 18)
FEF 25-75 831/-32 (n5 46) 441/-30 (n5 46) 571/-42 (n5 39) 531/-29 (n5 28) 501/-36 (n5 28) 571/-44 (n5 17) 411/-33 (n5 18)
DLCO 801/-16 (n5 41) 561/-12 (n5 39) 601/-15 (n5 31) 621/-15 (n5 21) 601/-15 (n5 16) 611/-16 (n5 12) 601/-15 (n5 16)
BO Stage
0 0 5 2 3 3 0
Potential BO 3 6 5 5 2 1
1 9 5 6 3 4 4
2 16 14 8 5 2 5
3 18 9 7 12 6 8montelukast. PFT changes over time are described in Table 1.
14/46 (30%) have died; with a median follow-up of 1.5 years
(range 0.13-3.97 years) from BO diagnosis, the median survival
from BO diagnosis has not been reached.
Conclusions: Patients receiving azithromycin in addition to stan-
dard therapy for BO maintained stable pulmonary function tests
for the first year following BO diagnosis. The generally favorable
survival following BO warrants further prospective research.310
THE ANCESTRAL HAPLOTYPE A1B8DR3 IS ASSOCIATED WITH IN-
CREASED INCIDENCE OF PULMONARY COMPLICATIONS AFTER ALLOGE-
NEIC HEMATOPOIETIC CELL TRANSPLANTATION (HCT)
Liu, J., Pukiat, S., Hahn, T., McCarthy, Battiwalla M., Jr, P.L. Roswell
Park Cancer Institute, Buffalo, NY
The 3 most common ancestral haplotypes in people of European
descent are A1B8DR3 (5.2%), A2B44DR4 (2.1%) and A3B7DR15
(2.6%). A1B8DR3 is associated with pulmonary autoimmune dis-
eases such as sarcoidosis and Wegener’s granulomatosis. Tumor
necrosis factor alpha (TNF-a) is the cytokine most frequently im-
plicated in the pathobiology of pulmonary complications after
HCT and TNF-a polymorphisms are strongly associated with
the A1B8DR3 haplotype. After observing several cases of pulmo-nary complications in A1B8DR3 patients, we conducted a retro-
spective cohort study to investigate the association of this
haplotype with pulmonary complications after allogeneic HCT.
From 1/1991 to 5/2005, 248 patients received an allogeneic
HCT from a related (N5 183) or unrelated (N5 65) peripheral
blood (n5 35) or marrow (n5 213) donor for myeloid (n5 159)
or lymphoid (n5 89) diseases. The A1B8DR3 haplotype was pres-
ent in 23 (9%), A2B44DR4 in 12 (5%) and A3B7DR15 in 19 (8%)
allogeneic HCT patients, which is higher than reported in normal
donors. Patient and treatment characteristics were: age at HCT 18-
40 years (n5 118, 48%), .40 years (n5 130, 52%); male (n5 155,
63%), European American (n5 234, 94%); KPS 90-100 (n5 159,
64%); VpCyTBI (n5 114), BuTBI (n5 27), BuCy (n5 27), Thio-
TBI (n5 22), CyTBI (n5 18); FluMel (n5 8); ThioCarbo (n5 8),
or Other (n5 24). Pulmonary complications included diffuse alve-
olar hemorrhage (DAH), bronchiolitis obliterans/lung GVHD
(BO/GVHD), viral or fungal pneumonia (VFPn), interstitial pneu-
monitis/ARDS/pleural effusion (IP/ARDS), and any one or more
of these pulmonary complications. There was no association of
A1B8DR3 with DAH or IP/ARDS, however BO/GVHD (17%
vs 4%, p5 0.017) and VFPn (30% vs 0%.p\0.001) were signifi-
cantly more common in patients with A1B8DR3. Any one or
more pulmonary complications was more common, but not signif-
icantly different, in patients with A1B8DR3 (48% vs 32%,
p5 0.16). Conversely, patients with the A2B44DR4 haplotype de-
veloped no pulmonary complications of any kind (0% vs 35%,
p5 0.013). There was no association of A3B7DR15 haplotype
with any pulmonary complications. There was no significant inter-
action for lymphoid/myeloid disease, related/unrelated donor or
male/female recipient between A1B8DR3 and any pulmonary com-
plications. Investigating the relationship between HLA haplotypeand outcome may improve our understanding of the pathogenesis
of pulmonary complications and provide individualized screening
and treatment for this adverse outcome.311
IMPROVED OUTCOME AFTER REDUCED INTENSITY ALLOGENEIC HEMA-
TOPOIETIC STEM CELL TRANSPLANT (RI-HCT) FOR MDS USING TACRO-
LIMUS/SIROLIMUS AS GVHD PROPHYLAXIS
Nakamura, R.1, Palmer, J.2, Chao, J.1, Stiller, T.2, Pullarkat, V.1,
Parker, P.1, Stein, A.1, Snyder, D.1, Cai, J.-L.1, Bhatia, R.1,
Chang, K.3, Wang, S.4, Senitzer, D.1, Forman, S.J.1,
O’Donnell, M.R.1 1City of Hope National Medical Center, Duarte, CA;
2City of Hope National Medical Center, Duarte, CA; 3City of Hope Na-
tional Medical Center, Duarte, CA; 4City of Hope National Medical Cen-
ter, Duarte, CA
We previously reported an encouraging result with RI-HCT
for MDS (Bone Marrow Transplant 2007) using fludarabine/mel-
phalan (Flu/Mel) conditioning and cyclosporine (CSA)/mycophe-
nolate (MMF) as GVHD prophylaxis. In order to further
improve upon the outcome in the RI-HCT setting, we initiated
a series of clinical trials at City of Hope designed to evaluate the
impact of tacrolimus (FK)/sirolimus (SIR)-based GVHD
